BioSpace News Archive

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2020 Sustainability Report. The report highlights the company’s continued commitment and progress on environmental, social and governance (ESG) initiatives.

Biomarck Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company focused on developing peptides that inhibit MARCKS to treat patients with inflammatory diseases, today announced that data from pre-clinical studies of the Company’s proprietary peptides will be presented on Thursday, May 6, 2021 during the 2021 ARVO (Association for Research in Vision and Ophthalmology) Annual Meeting, May 1 – 7, 2021.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq:INM) (TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that, based on the strong trading data on the Nasdaq, it has provided written notice to the Toronto Stock Exchange (the “TSX”) regarding the voluntary delisting of its common shares.

Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that it plans to report its first quarter 2021 financial results and other business updates on May 6, 2021.

Arch Therapeutics, Inc. (OTCQB: ARTH) (“ Arch ” or the “ Company ”), developer of novel self-assembling wound care and biosurgical devices, today announced that two clinical case report abstracts of AC5 ® Advanced Wound System will be presented at the upcoming 2021 Symposium on Advanced Wound Care (SAWC).

Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients

Bright Minds Biosciences (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced two additions to its leadership team and one new scientific advisor as follows

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that new data highlights from three patients with pediatric growth hormone deficiency (PGHD) previously treated with the company’s lead asset LUM-201 will be presented during a virtual key opinion leader (KOL) event to be held today, April 27, 2021,

Study concludes the utilization of T2 Magnetic Resonance (T2MR®) provides faster time to detection, faster time to targeted therapy, and shortened ICU and hospital length-of-stay

Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the first quarter ended March 31, 2021 before market open on Thursday, May 13, 2021.